Pyrotinib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	49	26	15	96	—	—	2013-01
Malignant Breast Neoplasm	Phase4	Phase 4	29	13	9	58	—	—	2013-01
Malignant Lung Neoplasm	Phase2	Phase 2	4	2	0	8	—	—	2015-01
Malignant Gastric Neoplasm	Phase1	Phase 1	0	0	0	1	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ZNF880 Fusion1
Pyrotinib	HER2-Positive Breast Carcinoma

Clinical trials

Trials with this intervention (107)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 107 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07836257	A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd	not yet recruiting	Phase 2	28	Fujian Medical UniversityOTHER	1	Sep 23, 2026	clinicaltrials
NCT05745740	A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation	not yet recruiting